Comparision of the Side Effects Due To Interferon Alpha 2A Plus Ribavirin and Pegylated Interferon Alpha 2A Plus Ribavirin Combinations For Chronic Hepatitis C Infection

被引:2
作者
Ural, Onur
Demir, Nazlim Aktug
Sumer, Sua
Ural, Gaye
Balci, Mehmet
机构
[1] Selcuk Univ, Meram Tip Fak, Dept Clin Bacteriol & Infect Dis, TR-42080 Konya, Turkey
[2] Numune Hosp, Dept Clin Bacteriol & Infect Dis, Konya, Turkey
[3] Hopa State Hosp, Dept Clin Bacteriol & Infect Dis, Arvin, CA USA
[4] Duzici State Hosp, Dept Clin Bacteriol & Infect Dis, Osmaniye, Turkey
来源
TRAKYA UNIVERSITESI TIP FAKULTESI DERGISI | 2010年 / 27卷 / 03期
关键词
Pegylated interferon alpha 2a+ribavirin; interferon alpha 2a+ribavirin; side effects; VIRUS-INFECTION; THERAPY; TRIAL;
D O I
10.5174/tutfd.2009.02005.1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: Comparision of the side effects due to interferon alpha 2a plus ribavirin and pegylated interferon alpha 2a plus ribavirin combinations for chronic hepatitis C infection. Patients and Methods: In this study, 36 patients, who received interferon alpha 2a, 3 million U, subcutaneously thrice weekly plus oral ribavirin 1000-1200 mg daily were compared with 49 patients, who received pegylated interferon alpha 2a 180 mu gr, subcutaneously once weekly plus oral ribavirin 1000-1200 mg daily with respect to side effects. Results: Lack of appetite, headache and fatigue were more frequent in pegylated interferon alpha group, and these differences between groups were statistically significant (p<0.05). Conclusion: In our study the treatment is discontinued in two patients who received interferon plus ribavirin (anemia in one, both anemia and thrombocytopenia in the other) and three patients, who were treated with pegylated interferon plus ribavirin (anemia in one, both anemia and thrombocytopenia in one and psychiatric problems in the other).
引用
收藏
页码:261 / 264
页数:4
相关论文
共 22 条
[1]   Epoetin alfa maintains ribavirin dose in HCV-infected patients: A prospective, double-blind, randomized controlled study [J].
Afdhal, NH ;
Dieterich, DT ;
Pockros, PJ ;
Schiff, ER ;
Shiffman, ML ;
Sulkowski, MS ;
Wright, T ;
Younossi, Z ;
Goon, BL ;
Tang, KL ;
Bowers, PJ .
GASTROENTEROLOGY, 2004, 126 (05) :1302-1311
[2]   Review article: the management of side-effects during therapy for hepatitis C [J].
Aspinall, RJ ;
Pockros, PJ .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 20 (09) :917-929
[3]   Long-term outcome of interferon-α-induced thyroid autoimmunity and prognostic influence of thyroid autoantibody pattern at the end of treatment [J].
Carella, C ;
Mazziotti, G ;
Morisco, F ;
Manganella, G ;
Rotondi, M ;
Tuccillo, C ;
Sorvillo, F ;
Caporaso, N ;
Amato, G .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (05) :1925-1929
[4]   Randomized controlled trial of recombinant human granulocyte-macrophage colony-stimulating factor for the treatment of chronic hepatitis C [J].
Carreño, V ;
Martín, J ;
Pardo, M ;
Brotons, A ;
Anchía, P ;
Navas, S ;
Fernández, M ;
Arocena, C ;
Quiroga, JA .
CYTOKINE, 2000, 12 (02) :165-170
[5]   The use of growth factors to manage the hematologic side effects of PEG-interferon alfa and ribavirin [J].
Collantes, RS ;
Younossi, ZM .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 2005, 39 (01) :S9-S13
[6]   Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: Role of membrane oxidative damage [J].
De Franceschi, L ;
Fattovich, G ;
Turrini, F ;
Ayi, K ;
Brugnara, C ;
Manzato, F ;
Noventa, F ;
Stanzial, AM ;
Solero, P ;
Corrocher, R .
HEPATOLOGY, 2000, 31 (04) :997-1004
[7]  
DEMIR K, 2003, NOBEL MEDIKUS, V3, P27
[8]  
DINCER D, 2005, GUNCEL GASTROENTEROL, V9, P258
[9]  
DINCER D, 2000, VIRAL HEPATIT DERGIS, V6, P172
[10]   THERAPY OF HEPATITIS-C [J].
FRIED, MW ;
HOOFNAGLE, JH .
SEMINARS IN LIVER DISEASE, 1995, 15 (01) :82-91